```html

Xerogenic Keratitis: A Comprehensive Medical Guide

Overview

Xerogenic keratitis (also called dry‑eye‑related keratitis) is an inflammation of the cornea that occurs secondary to severe ocular surface dryness. The cornea, the clear front surface of the eye, requires a stable tear film to stay healthy and clear. When tear production or distribution is insufficient, the corneal epithelium can become damaged, leading to inflammation, ulceration, and vision loss.

Who it affects: The condition is most common in adults over 40 years of age, especially women, because hormonal changes (e.g., menopause) reduce tear production. It also appears in people with autoimmune diseases (Sjögren’s syndrome, rheumatoid arthritis), long‑term contact‑lens wearers, and those who undergo refractive surgery.

Prevalence: According to the National Eye Institute, dry eye disease— the primary driver of xerogenic keratitis—affects an estimated 5–30% of the U.S. population. Of those, up to 15% develop corneal complications such as xerogenic keratitis. Worldwide, prevalence figures rise to 30–40% in older adults, highlighting the public‑health importance of early detection and management.<sup>[1][2]</sup>

Symptoms

The presentation can be subtle at first and progress rapidly if untreated. Common symptoms include:

• Burning or stinging sensation – a feeling of heat on the eye surface.
• Foreign‑body sensation – the impression that something is “in” the eye.
• Blurred vision – often worse at the end of the day or after prolonged visual tasks.
• Photophobia – increased sensitivity to light.
• Redness – conjunctival injection surrounding the cornea.
• Excessive tearing (reflex tearing) – paradoxical watery eyes as a response to irritation.
• Sticky or crusted eyelids – especially upon waking.
• Decreased tear meniscus height – visible when the lower eyelid is pulled down.
• Corneal epithelial defects – may be detected as small, irregularly shaped spots on fluorescein staining.
• Pain or deep aching – usually indicates that the inflammation has progressed to involve deeper corneal layers.

Causes and Risk Factors

Xerogenic keratitis is not a primary disease; it results from conditions that compromise the tear film.

Primary Causes

• Aqueous‑deficient dry eye – insufficient tear production due to lacrimal gland dysfunction (e.g., Sjögren’s syndrome, aging).
• Evanescent‑tear (Meibomian gland) dysfunction – poor lipid layer leads to rapid evaporation.
• Environmental exposure – low humidity, wind, air‑conditioned or heated rooms.
• Medication side‑effects – antihistamines, isotretinoin, antidepressants, and some antihypertensives reduce tear secretion.
• Limbal stem‑cell deficiency – after ocular surgery, chemical injury, or chronic inflammation.

Risk Factors

• Age > 40 years (tear production declines with age).
• Female gender – hormonal influences on lacrimal glands.
• Autoimmune systemic diseases (Sjögren’s, rheumatoid arthritis, lupus).
• Long‑term contact lens wear (especially low‑oxygen silicone hydrogel lenses).
• Prior ocular surgery (LASIK, PRK, cataract extraction).
• Screen‑time > 4 hours/day – reduced blink rate.
• Exposure to smoke, dust, or chemical fumes.

Diagnosis

Accurate diagnosis combines patient history, a thorough slit‑lamp examination, and specific tests to quantify tear film stability.

Clinical Evaluation

• History taking – medication review, systemic disease, occupational exposures.
• Visual acuity – baseline measurement to monitor progression.
• Slit‑lamp biomicroscopy – identifies fluorescein‑stained epithelial defects, stromal haze, or infiltrates.

Diagnostic Tests

• Schirmer I test – filter paper strips placed in the lower fornix for 5 minutes; <10 mm wetting suggests aqueous deficiency.
• Tear Break‑Up Time (TBUT) – fluorescein dye applied; time <10 seconds indicates tear instability.
• Ocular Surface Disease Index (OSDI) questionnaire – quantifies symptom severity.
• Lipid layer interferometry or meibography – evaluates Meibomian gland function.
• Corneal topography – assesses surface irregularities that may develop with chronic keratitis.

In atypical cases, cultures of the corneal ulcer or confocal microscopy may be ordered to exclude infectious keratitis.

Treatment Options

Management aims to restore a healthy tear film, reduce inflammation, and protect the corneal epithelium.

Medical Therapies

• Artificial tears – preservative‑free lubricants used 4–6 times daily; hyaluronic acid or carboxymethylcellulose formulas provide longer residence time.
• Lubricating ointments/gels – applied at night for extended coating.
• Cyclosporine A 0.05% (Restasis) or lifitegrast 5% (Xiidra) – immunomodulatory drops that increase tear production and reduce ocular surface inflammation.
• Topical corticosteroids – short‑course (e.g., prednisolone acetate 1%) to control acute inflammation; use under ophthalmologist supervision to avoid glaucoma or cataract.
• Tetracycline family oral antibiotics (doxycycline 40 mg daily) – anti‑matrix‑metalloproteinase effect that improves meibomian gland secretions.
• Autologous serum eye drops – contain growth factors and vitamin A; reserved for refractory epithelial defects.
• Punctal plugs – silicone or collagen plugs inserted into lacrimal puncta to retain tears.

Procedural Interventions

• Thermal pulsation (LipiFlow) – applies heat and massage to unblock Meibomian glands.
• Meibomian gland expression – performed in‑office to manually clear obstructed glands.
• Light‑based therapies (Intense Pulsed Light, IPL) – reduce inflammation and improve gland function.
• Amniotic membrane transplantation – for severe, non‑healing epithelial defects.
• Corneal bandage contact lenses – protect the surface while healing.

Lifestyle and Environmental Adjustments

• Increase ambient humidity (humidifiers).
• Take regular “blink breaks” during screen use (20‑20‑20 rule).
• Avoid smoke, wind, and direct air‑conditioner flow.
• Stay hydrated; limit caffeine and alcohol.

Living with Xerogenic Keratitis

Adapting daily habits can dramatically improve comfort and visual function.

• Morning routine – cleanse eyelids with warm compresses (5–10 minutes) followed by gentle lid massage to melt meibum.
• Lubrication schedule – use preservative‑free drops before and after screen work; reapply every 2–3 hours if needed.
• Protective eyewear – wrap‑around glasses in windy or dry environments reduce evaporation.
• Contact lens considerations – switch to daily‑disposable lenses or discontinue use during flare‑ups.
• Medication review – discuss with your physician whether any systemic drugs could be contributing to dryness.
• Follow‑up appointments – regular ophthalmology visits (every 3–6 months) allow early detection of worsening disease.

Prevention

While some risk factors (age, genetics) are unavoidable, many strategies can lower the likelihood of developing xerogenic keratitis.

1. Maintain optimal blink rate – practice conscious blinking during prolonged reading or computer work.
2. Use omega‑3 fatty acid supplements (1 g EPA/DHA daily) – modest evidence supports improved Meibomian gland secretions.<sup>[3]</sup>
3. Keep indoor humidity between 40–60 %.
4. Avoid over‑use of preserved eye drops; choose preservative‑free options for chronic use.
5. Schedule anti‑inflammatory eye drops (e.g., cyclosporine) before the onset of symptoms if you have known dry‑eye disease.
6. Wear sunglasses outdoors to protect against UV‑induced ocular surface inflammation.

Complications

If untreated, xerogenic keratitis can lead to serious ocular sequelae:

• Recurrent corneal erosions – painful episodes of epithelial breakdown.
• Corneal ulceration – risk of secondary bacterial or fungal infection.
• Scarring (nebular or stromal opacity) – permanent visual distortion.
• Neovascularization – ingrowth of new blood vessels into the cornea, compromising transparency.
• Reduced visual acuity – especially if the visual axis is involved.
• Dry‑eye‑related glaucoma or cataract progression – chronic inflammation can accelerate other age‑related eye diseases.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Dry eye syndrome.” Updated 2023. https://www.mayoclinic.org/dry-eye-symptoms-causes/syc-20371863
2. National Eye Institute. “Dry Eye.” 2022. https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/dry-eye
3. American Academy of Ophthalmology. “Management of Dry Eye Disease.” 2021. https://www.aao.org/eye-health/diseases/dry-eye-management
4. American College of Ophthalmology Clinical Guidelines. “Keratitis.” 2020.
5. World Health Organization. “Global data on visual impairment.” 2020.

```